Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Patented mucoadhesive for cannabis studies https://www.google.com/patents/US20060039959
This is the same delivery system BDSI has in place-minus a few tweaks...this lawsuit shall bring some eyes to say the least
"Government to invest 1 billion in fight against opioid addiction plague"
http://www.minyanville.com/business-news/markets/articles/2524BIVI-biotechnology-2524IGXT-2524SPHS-2524BDSI-2524AVXL/12/20/2016/id/59038
White House To Loosen Controls On Heroin Addiction Treatment
Taylor Cox , Benzinga Staff Writer-July 06, 2016 9:00am
Click For Article
The Wall Street Journal recently reported President Obama’s administration will loosen its strict controls on a medication called buprenorphine, which is used to treat addiction to heroin and other opioid-based drugs.
The Department of Health and Human Services up until now only allowed doctors to prescribe the medication to 100 patients at a time. Under the new rules, up to 275 patients at a time can be prescribed the drug. The limits were designed to restrict access to the substance, which addicts sometimes trade on the black market to opioid abusers seeking to avoid painful withdrawal symptoms. An unintended consequence to the tight controls became the inability/difficulties of finding a legal way to obtain the medicine from a doctor.
Related Link: Heat Wave: Here's How The S&P Has Performed Every July Since The Financial Crisis
This could spell good news for companies like Titan Pharmaceuticals, Inc.
TTNP 0.85%
and BioDelivery Sciences International, Inc.
BDSI 4.26%
, two companies that have been working on an injectable form of buprenorphine.
Titan recently received approval from the FDA for the first injectable implant in the United States, which will deliver a dosage of the medicine to patients, especially those who find methadone to be too addicting.
Shares of both Titan and BioDelivery over the last month have spiked but fallen to remain pretty much flat; however, this news may be a catalyst for these two pharmaceuticals.
Blessings to All
TRUTH
True, but would have rather sold when it was in the $2.90's a month ago and bought back when it was in the $2.20's. Actually have been bid sitting on BDSI many days but hasn't gone low enough. Market too volatile to hold very long for my taste (look at BDSI from early today till now).
BDSI is in the right place.
A little patience, goes a long way.
Blessings to All
TRUTH
Sold @ $1.97 for small profit. The $1.95 did not hold and seems some institution is keen on selling. Been down while bios have been up for the past several days. Hope to re-buy at more favorable pps.
BDSI
BUYING BDSI. GOOD NEWS
Thanks for the breakdown. Always appreciate your charting
* * $BDSI Video Chart 03-30-16 * *
Link to Video - click here to watch the technical chart video
Get ready for a big move in the coming weeks boys and girls. Chart looks beautiful with a monster candle among others! $bdsi
institutional ownership is at about %88 and short interest has declined and weakened...
BDSI moving up and will hit $6 to $7.50 by end of Feb. after Belbuca launch and investor day in Feb....
Nows the time to get in...
BDSI continues on it's trend upward...
will be hosting an investor day in Feb.
May be to late to buy in early by then as BDSI moves up...
belbuca set to launch in Feb. thru ENDP who is spearheading the launch and has set milestone payments for sales and also a $50 million milestone payment paid for the FDA approval of Belbuca..
ENDP is in the process of setting up sales for Belbuca of which a majority of it's resources and sales force is geared up to the launch...
time to get in now...
updated short interest shows a decline and 13 g filed for Armistice Capital with a enormous increase in shares...
BDSI making a move upward....
new 13 G last week reveals that hedge funds and institutions are increasing their stakes in BDSI...
Belbuca set to launch soon with ENDP, which will give traction to BDSI on it's upward trend....
$50 million milestone payment from ENDP gives BDSI cash on hand for it's financials...
ENDP has increased it's sales and marketing staff for the Belbuca launch..
short interest has decreased and BDSI has started a move up after hitting a low of $3.03ish
Shorts relying on frustrated longs to let them off the hook. BDSI has been a tuff LT hold but we are starting to see bursts of shorts covering...tells me they know time is running out. I expect these dips below $6 to be a thing of the past as they tend to be quickly bought up. patience patience patience...we are almost there!
Over time BDSI should be able to reach that PPS. They just had a new drug FDA approved. Thus, it will take time before the earning increase materialize and PPS increases.
Cheers
Its not my price target. That was Posted. Take a look
10:33 AM EST, 11/04/2015 (MT Newswires) -- BioDelivery Sciences International(BDSI) shares were initiated by Cantor with a buy rating and a price target set at $14.
Hard to predict earnings IMO. I think we might also get a contraction in PPS and then a rebound. Your target price will take some time to react - may 6-12 months. JMO
Some shorts trying hard to hold this down but we will see a nice end of day pop after yesterdays aftermarket performance. To many eyes watched FOLD explode two days before earnings.
price target $16. Are earnings expect to be good?
Agreed. We might have another good day of gains. Some of this may be due to shorts covering and some with the market focused on biotech/pharm companies.
It went over $6.00 aftermarket, lets see if it can hold and continue upwards. BDSI
* * $BDSI Video Chart 11-03-15 * *
Link to Video - click here to watch the technical chart video
PPS is slowly increasing today. It might close above $6. Next week they release the financial statements.
Hopefully good news soon to change the direction of PPS.
* * $BDSI Video Chart 10-28-15 * *
Link to Video - click here to watch the technical chart video
* * $BDSI Video Chart 10-27-15 * *
Link to Video - click here to watch the technical chart video
$BDSI 5.4 need hold , bears pushing (3mil short yesterday ) , I think they have to cover soon, news are great.
Good chance that ENDP will eventually buy out this company instead of paying out the 50mil plus royalties and future milestones. The question is at what price. GL
* * $BDSI Video Chart 10-26-15 * *
Link to Video - click here to watch the technical chart video
Stack. Dunno about this FDA approval BS.
Bought one about 6 months ago fresh out of the gate.
Wham, went down 30% before I could say Jack Robinson.
Bought BDSI this AM for $6.04, now $5.72 - bummer !
How is it being pushed down even with a FDA approval? It should at least gain a dollar :/
FDA approval should help push this stock higher today.
this is the so awaited NEWS !!! big one !!BDSI should push over 7 $ today ~
U.S. FDA Approves BELBUCA™ (buprenorphine) Buccal Film for Chronic Pain Management http://finance.yahoo.com/news/u-fda-approves-belbuca-buprenorphine-100000839.html
Approved see @investor666 on twitter
company held news for cronies/hedgies/family/friends to unload...
looks like FDA rejected- either short or get out while u can
Can't blame you for locking profits. I'm sticking because I think approval odds are high and with that comes a 50 million payment and a nice chunk of sales. No more dry powder but I'll stand pat for now.
BDSI There was news yesterday.. and expecting FDA news by next Friday. There can't be news every day.
No worries Pong, with only three ihub posts, you are not expected to know this.
Reload, imo.
MG
I'm out..taking my money and running :). good luck
I will say $7 on Monday and then continue to slowly climb before the news on Wednesday. Top end ~9 on Wed. JMO
Followers
|
46
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
408
|
Created
|
06/14/09
|
Type
|
Free
|
Moderators |
http://www.bdsinternational.com/
http://finance.yahoo.com/q/ks?s=BDSI
BioDelivery Sciences International, Inc. operates as a specialty pharmaceutical company in the United States. Its patented drug delivery technologies include BEMA drug delivery technology and Bioral cochleate drug delivery technology. The company, using its drug delivery technologies, develops formulations of pharmaceuticals aimed principally at short term acute conditions occurring in patients, primarily in the areas of pain and fungal infections. Its lead product is ONSOLIS, a treatment for pain in opioid tolerant patients with cancer. BioDelivery Sciences licensed the commercialization and distribution rights for ONSOLIS to Meda AB. The company’s products/formulations also include BEMA Buprenorphine, which is under preparation for phase 2 for moderate to severe and acute pain. Its lead Bioral formulation is an encochleated version of Amphotericin B, an anti-fungal treatment for systemic fungal infections. The company also has a Bioral formulation, which is in initial in vitro studies for the intranasal administration of Amphotericin B to treat chronic rhinosinusitis. BioDelivery Sciences has a research collaboration and licensing agreement with the Drugs for Neglected Diseases initiative (DNDi) to develop Bioral Amphotericin B for the treatment of neglected diseases, such as leishmaniasis and Chagas disease. The company was founded in 1997 and is based in Raleigh, North Carolina.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |